Brincidofovir (alias CMX001), an API developed and manufactured by Poly Pharm., has continued to develop customers since its successful development, and has now completed kilogram orders from international customers and delivered successfully. New orders are being scheduled and will be delivered on schedule.
Anhui Poly, a wholly-owned subsidiary of Hainan Poly Pharm. Co., Ltd (hereinafter referred to as "the Company"), has recently received the “the Notice of Drug GMP Compliance Inspection Results" (hereinafter referred to as "the Notice") issued by Anhui Center for Drug Evaluation, the product involved is: API (Gadoterate meglumine).
Poly Pharm. has successfully developed Salidroside (Scientific name 2-(4-hydroxyphenyl) ethyl-β-D-glucopyranoside), a raw material for drugs, cosmetics and health care products, through synthetic biology technology. The product is obtained by fermentation of genetically engineered strains of bacteria, and the purity reaches more than 98%.
